Namsa – FDA 483, Sep 21, 2021

Hanza, a nonclinical laboratory in Minneapolis, MN, was inspected by the FDA, resulting in one observation. The firm failed to retain all required documentation records, raw data, and specimens from nonclinical laboratory studies in the archives for the appropriate time. This practice was contrary to GLP retention requirements and firm procedures.